John M. Clements
British Biotech Pharmaceuticals Ltd.
Oxford OX4 6LY
United Kingdom
Name/email consistency: high
- Antibacterial activities and characterization of novel inhibitors of LpxC. Clements, J.M., Coignard, F., Johnson, I., Chandler, S., Palan, S., Waller, A., Wijkmans, J., Hunter, M.G. Antimicrob. Agents Chemother. (2002)
- Antibiotic activity and characterization of BB-3497, a novel peptide deformylase inhibitor. Clements, J.M., Beckett, R.P., Brown, A., Catlin, G., Lobell, M., Palan, S., Thomas, W., Whittaker, M., Wood, S., Salama, S., Baker, P.J., Rodgers, H.F., Barynin, V., Rice, D.W., Hunter, M.G. Antimicrob. Agents Chemother. (2001)
- Matrix metalloproteinase expression during experimental autoimmune encephalomyelitis and effects of a combined matrix metalloproteinase and tumour necrosis factor-alpha inhibitor. Clements, J.M., Cossins, J.A., Wells, G.M., Corkill, D.J., Helfrich, K., Wood, L.M., Pigott, R., Stabler, G., Ward, G.A., Gearing, A.J., Miller, K.M. J. Neuroimmunol. (1997)